title: [The INCA trial (impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites): precision medicine for patients with liver cirrhosis and ascites].
authors.forename: M
authors.initials: M
authors.lastname: Casper
authors.forename: B
authors.initials: B
authors.lastname: Appenrodt
authors.forename: F
authors.initials: F
authors.lastname: Grünhage
authors.forename: F
authors.initials: F
authors.lastname: Lammert
mesh_terms: D000368:Aged; D019072:Antibiotic Prophylaxis / Q000401:mortality*; D001201:Ascites / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D001424:Bacterial Infections / Q000235:genetics* / Q000401:mortality* / Q000517:prevention & control; D015984:Causality; D002985:Clinical Protocols; D015897:Comorbidity; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics*; D018802:Patient-Centered Care / Q000706:statistics & numerical data; D015995:Prevalence; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein